ViiV Healthcare has announced that the European Commission has approved Dovato (dolutegravir / lamivudine) for the treatment of HIV-1 infection in adults and adolescents aged 12 years and over 40 kg body weight. Patients must not have any known or suspected resistance to integrase inhibitors or lamivudine. The EU approval of Dovato is based on data from the global GEMINI-1 and -2 studies, which included more than 1,400 HIV-1 infected, treatment-naïve adults. In these studies, the combination of dolutegravir (DTG) and lamivudine (3TC) was virologically not inferior to tenofovir disoproxil fumarate / emtricitabine (TDF / FTC) compared to triple therapy consisting of dolutegravir and the nucleoside reverse transcriptase inhibitors (NRTIs) at week 48 (proportion of patients with plasma HIV-1 RNA
Source: ViiV Healthcare GmbH, www.viivhealthcare.com
7
0
Do you want a website?